報價延遲最少15分鐘:2026/04/18 06:37 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
83.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.41/6.72
|
|
企業價值
6.08B
|
| 資產負債 |
|
每股賬面淨值
16.74
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
1.54B
|
|
每股收益
18.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, PrecisionDiagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements inEurope, Canada, Australia, Asia-Pacific, Central America and South America. |
